XML 121 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Geographic Information
 12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Geographic Information Grant Revenue
In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $56.4 million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of December 31, 2020, the committed funding, net of revenue earned was $4.6 million, with an additional $51.4 million available if DARPA exercises additional contract options.

In April 2020, we entered into an agreement with BARDA for an award of up to $483.3 million to accelerate development of mRNA-1273, our vaccine candidate against COVID-19. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $471.6 million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. The amendment increased the maximum award from BARDA from $483.3 million to $954.9 million. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of December 31, 2020, the remaining available funding net of revenue earned was $444.3 million.

In September 2016, we received an award of up to $125.8 million from BARDA, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of December 31, 2020, the remaining available funding net of revenue earned was $70.8 million, with an additional $8.4 million available if the final contract option is exercised.

In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of December 31, 2020, the available funding net of revenue earned was $11.4 million, with up to an additional $80.0 million available if additional follow-on projects are approved.
The following tables summarize grant revenue and deferred grant revenue for and as of the periods presented (in thousands):

Years Ended
202020192018
BARDA$521,652 $7,608 $6,736 
Other grant revenue7,253 4,565 5,820 
Total grant revenue$528,905 $12,173 $12,556 


December 31,
20202019
Deferred grant revenue$5,261 $2,777 
Product Sales
In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international government agencies. Under the supply agreements with these government agencies, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory.

Product sales by customer geographic location was as follows (in thousands):
Year Ended December 31, 2020
United States$193,630 
Rest of world6,242 
Total $199,872 

There were no product sales in 2019 and 2018. We had one commercial product, our COVID-19 vaccine, authorized for use as of December 31, 2020.
As of December 31, 2020, we had deferred revenue of $3.80 billion related to customer deposits, classified as current deferred revenue in our consolidated balance sheet. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.Geographic Information
Geographic Revenue

We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.

Total revenue by geographic area of our customers and collaboration partners was as follows (in thousands):

Years Ended December 31,
202020192018
United States$764,529 $54,976 $89,075 
Rest of world38,866 5,233 45,993 
Total $803,395 $60,209 $135,068 

Our property and equipment, including financing right-of-use asset, were principally located within the United States as of December 31, 2020 and 2019.